Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- 177Lu-PSMA-617 (Pluvicto) Combo With Sipulecel-T in Phase 1 Trial November 1, 2025
- News pre|CISION Platform: Delivering Two Complementary Therapies from One Molecule October 27, 2025
- Helicon Degraders Show a New Path in Prostate Cancer Therapy October 27, 2025
- UPDATE 2: HLD-0915 Shows Promising Early Results in Drug-Resistant Prostate Cancer October 27, 2025
TD001: a New Potent ADC for Prostate Cancer Expressing PSMA
/in Antibody-Drug Conjugate, Preclinical Research/by MaxPredictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/in Drug repurposing, Preclinical Research/by MaxPhase 1 Soon Recruiting: MK-2400 (Ifinatamab Deruxtecan) for Metastatic Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 2 Trial Enrolling: Combination Therapy for Metastatic Castration-Resistant Prostate Cancer
/in Clinical Trial, Metastatic, Phase 2/by MaxPhase 1 Enrolling: Sylvester Cancer Center Launches Innovative Clinical Trial for High-Grade Neuroendocrine Tumors
/in Clinical Trial, Metastatic, Phase 1/by MaxAdvancements in Delivery: Gene Therapy Could Help Prostate Cancer Treatment
/in CRISPR, Delivery, Preclinical Research/by MaxUpdate: FC705 Signals a Leap Forward in Prostate Cancer Therapy, Outperforming Pluvicto
/in Clinical Trial, Metastatic, Phase 2/by Max